Evaluation of Female Fertility: AMH and Ovarian Reserve Testing

February 2022 in “ The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism ”

Marcelle I. Cedars

Antimüllerian hormone AMH ovarian reserve ovarian stimulation endocrine environment body mass index BMI

Studysummary This review discusses the use of antimüllerian hormone as a marker of ovarian reserve in infertility diagnosis and treatment, noting it reflects oocyte quantity but not health or pregnancy likelihood. Our plain-language summary of this paper — not a Tressless recommendation.

This narrative review discusses the role of Antimüllerian hormone (AMH) in evaluating female fertility, particularly as a marker of ovarian reserve. AMH correlates with the number of growing follicles and is used to estimate ovarian reserve, determine dosing in ovarian stimulation, and predict stimulation response. However, AMH does not reflect oocyte health or chances for pregnancy and should not be used to withhold treatment. Low AMH levels may indicate a shortened reproductive window but must be interpreted considering the endocrine environment and factors like body mass index. While AMH is a useful marker, age remains the most significant factor in determining fertility treatment success.

View this study on academic.oup.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research The Prevalence and Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

767 citations , September 2016 in “Human Reproduction”

This review analyzes the reported prevalence of polycystic ovary syndrome (PCOS) based on different diagnostic criteria but does not provide new clinical results.

The Prevalence of Polycystic Ovary Syndrome in a Normal Population According to the Rotterdam Criteria Versus Revised Criteria Including Anti-Mullerian Hormone

research The Prevalence of Polycystic Ovary Syndrome in a Normal Population According to the Rotterdam Criteria Versus Revised Criteria Including Anti-Mullerian Hormone

221 citations , January 2014 in “Human Reproduction”

This study found that the prevalence of polycystic ovary syndrome was 16.6% with Rotterdam criteria but decreased to 6.3% or 8.5% when using alternative criteria involving antral follicle count or anti-Müllerian hormone.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome

4809 citations , January 2004 in “Fertility and Sterility”

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.